News
- The SECA and Bioiberica Farma will again award the Innova prizes to recognize the work of innovative projects contributing to improvements in osteoarthritis management and patient care.
- Deadline for candidature submissions is July 31st 2014. The two prizes, each worth 10,000€, will be awarded on October 16th, during the SECA annual congress.
It is the first ever novel food approved in Spain. It is also a worlds first, because it is the first ingredient considered useful to preserve joint health. The rooster comb extract could be added to everyday consumption products such as milk, yoghurt or cheese. Bioiberica will sell it under the trademark Mobilee.
It is the first DNA test that predicts predisposition to rapid progression knee osteoarthritis.This award recognizes the research and innovation of the Spanish biotech company Bioiberica Farma, as well as their contribution to the improvement in the quality of life of Osteoarthritis (OA) patients.
The percentage of patients is even higher among those taking anti-inflammatory or COX-2 inhibitors to treat their osteoarthritis. Physicians still fail to take into account co-morbidity and risk factors associated withosteoarthritis. They are not aware of the risks associated withthe prescription of certain drugs.
A Phase IV, randomized, double blind, placebo controlled clinical test was presented at the 21st National congress of the Spanish Society of Clinical pharmacology. The procedure consisted of applying a painful stimulus to the patients knees, then used functional magnetic resonance to measure the brains reaction to pain.